

SUPPLEMENTARY MATERIAL

Supplemental Table. Literature review of corticosteroid-dependent/resistant cases of drug eruptions with dupilumab. Dupi, dupilumab; M, male; F, female; EOS, eosinophil; BP, bullous pemphigoid; TAD, transient acantholytic dermatosis; CTCL, cutaneous T-cell lymphoma.

Author	Age, sex	Suspect Drug	Primary disease	Drug rash	Lab evidence	Systemic steroid	Other side effects	Rash resolved with Dupi	Suspect drug resumed
Current case	18, F	Buspirone and oxcarbazepine	Anxiety	DRESS	IgE and IL-4 ⁺ IL-13 ⁺ CD4 ⁺ T cell increased	Dependent	Moon face developed	Y	-
Kuo ¹	62, M	Lenalidomide	Multiple myeloma	Eczematous rash	-	Dependent	Lenalidomide stopped	Y	Y
	75, M	Lenalidomide	Multiple myeloma	Eczematous rash	EOS% 11.7	Dependent	Lenalidomide stopped	Y	Y
	58, M	Lenalidomide	Multiple myeloma	Eczematous rash	EOS% 18.4	Dependent	Lenalidomide stopped	Y	Y
Megna ²	36, F	Ixekizumab	Psoriasis	Eczematous rash	IL-4 increased	Resistant	Ixekizumab stopped	Y	-
Napolitano ³	62, M	Ixekizumab	Psoriasis	Erythematous rash with exudation	IgE 1,400kU/L	Resistant	Ixekizumab stopped	Y	-
Koschitzky ⁴	42, M	Tildrakizumab	Psoriasis	Eczematous rash	-	Resistant	Tildrakizumab stopped	Y	Y
	54, F	Ixekizumab	Psoriasis	Eczematous rash	-	Resistant	Ixekizumab stopped	Y	Y
	24, F	Ustekinumab	Crohn's disease	Eczematous rash	Biopsy evidence	Resistant	Ustekinumab stopped	Y	Y
Klepper ⁵	79, F	Nivolumab	Melanoma	BP	Biopsy evidence	Intolerant	Moon facies and elevated blood pressure developed	Y	-
Bruni ⁶	76, M	Nivolumab	Melanoma	BP	EOS 0.96 G/L	Dependent	Nivolumab interrupted	Y	Y
Pop ⁷	59, F	Pembrolizumab	Cervical cancer	BP	-	Dependent	Pembrolizumab stopped	Y	-
Shelton ⁸	71, M	Ipilimumab and nivolumab	Metastatic renal cell carcinoma	TAD	Biopsy evidence	Resistant	Nivolumab stopped	Y	Y
Trum ⁹	26, M	Mogamulizumab	CTCL	Lichenoid rash	Biopsy evidence	Resistant	Mogamulizumab stopped	Y	-

Supplemental Reference:

1. Kuo AM, Hassoun H, Shah U, et al. Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma. *Leuk Lymphoma*. 2022;63:2233-7.
2. Megna M, Caiazzo G, Parisi M, et al. Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role? *Clin Exp Dermatol*. 2022;47:918-25.
3. Napolitano M, Gallo L, Patruno C, Fabbrocini G, Megna M. Eczematous reaction to ixekizumab successfully treated with dupilumab. *Dermatol Ther*. 2020;33(2):e13218.
4. Koschitzky M, Tan K, Noliza Encarnacion MR, Rivera-Oyola R, Khattri S. Eczematous reactions to psoriasis biologics treated with dupilumab: A case series. *JAAD Case Rep*. 2021;11:29-32.
5. Klepper EM, Robinson HN. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature. *Dermatol Online J*. 2021;27.doi:10.5070/D327955136.
6. Bruni M, Moar A, Schena D, Girolomoni G. A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab. *Dermatol Online J*. 2022;28.doi:10.5070/D328257396.
7. Pop SR, Strock D, Smith RJ. Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: A case report. *Dermatol Ther*. 2022;35:e15623.
8. Shelton E, Doolittle C, Shinohara MM, Thompson JA, Moshiri AS. Can't handle the itch? Refractory immunotherapy-related transient acantholytic dermatosis: prompt resolution with dupilumab. *JAAD Case Rep*. 2022;22:31-3.
9. Trum NA, Zain J, Abad C, Rosen ST. Dupilumab as a therapy option for treatment refractory mogamulizumab-associated rash. *JAAD Case Rep*. 2021;14:37-42.